Clinical Trials
26 trialsNCT04305054 2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT04253080 2026-05-20
ENZYMELA
Assistance Publique - Hôpitaux de Paris
Phase NA Completed
NCT03293784 2026-03-30
TICIMEL
Institut Claudius Regaud
Phase 1 Completed
NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
NCT03911557 2025-11-12
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
University of Kentucky
Phase 2 Completed
NCT03638141 2025-08-17
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04868708 2025-03-04
A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Akeso
Phase 2 Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT02046733 2024-11-08
STIMULI
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03852251 2024-08-02
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Akeso
Phase 1/2 Completed
NCT02970981 2024-04-30
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NYU Langone Health
Phase 2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03302234 2023-09-26
KEYNOTE-598
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03639714 2023-09-13
A Study of a Personalized Neoantigen Cancer Vaccine
Gritstone bio, Inc.
Phase 1/2 Completed
NCT03953235 2023-09-13
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
Gritstone bio, Inc.
Phase 1/2 Completed
NCT03408587 2023-05-06
CLEVER
Viralytics
Phase 1 Completed
NCT03507699 2023-04-18
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
Sheba Medical Center
Phase 1 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT02821754 2023-03-28
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03084471 2022-12-22
STRONG
AstraZeneca
Phase 3 Completed
NCT01896869 2020-05-19
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00836407 2020-02-24
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02705482 2019-08-26
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT03549546 2019-07-26
POIR
Centre Hospitalier Universitaire de Saint Etienne
Phase NA Completed
NCT01331525 2016-04-14
ICE
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed
NCT00028431 2014-05-22
Novel Adjuvants for Peptide-Based Melanoma Vaccines
University of Southern California
Phase 1 Completed